MARKET

KNSA

KNSA

Kiniksa Pharmaceuticals, Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.76
-0.95
-5.08%
After Hours: 17.76 0 0.00% 16:00 12/04 EST
OPEN
18.85
PREV CLOSE
18.71
HIGH
18.85
LOW
17.41
VOLUME
277.47K
TURNOVER
--
52 WEEK HIGH
28.67
52 WEEK LOW
9.50
MARKET CAP
1.21B
P/E (TTM)
-7.4990
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study
Kiniksa Pharmaceuticals ([[KNSA]] -1.3%) has reported preliminary data from Phase 1 trial evaluating KPL-404 in healthy volunteers. Final data and safety follow-up from all cohorts of the Phase 1 study is
Seekingalpha · 5d ago
Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
- Receptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous – - Data to-date support subsequent study in patients, including potential intravenous or subcutaneous monthly administration -
Receptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous – - Data to-date support subsequent study in patients, including potential intravenous or subcutaneous monthly administration - · 5d ago
Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 8:50 a.m. Eastern Time.
GlobeNewswire · 11/24 13:00
Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference
HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st, 2020 at 8:50 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.About Kiniksa Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.Every Second Counts!™ Kiniksa Investor and Media Contact Mark Ragosa (781) 430-8289 mragosa@kiniksa.com
GlobeNewswire · 11/24 13:00
Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
- PDUFA goal date of March 21, 2021 - - Filing based on positive data from RHAPSODY, which achieved its primary and all major secondary endpoints - - Rilonacept BLA for CAPS transferred to Kiniksa from Regeneron
PDUFA goal date of March 21, 2021 - - Filing based on positive data from RHAPSODY, which achieved its primary and all major secondary endpoints - - Rilonacept BLA for CAPS transferred to Kiniksa from Regeneron · 11/23 13:01
Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
- PDUFA goal date of March 21, 2021 -
GlobeNewswire · 11/23 13:00
Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020
KiniksaPharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that data from RHAPSODY, the pivotal Phase 3 trial of rilonacept in recurrent pericarditis, were published in The New England Journal of Medicine. Additionally, the RHAPSODY data were presented at the late-breaking science session during the American Heart Association (AHA) Scientific Sessions 2020. Kiniksa previously reported positive top-line RHAPSODY results in June 2020. Rilonacept is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1B) signaling.
GlobeNewswire · 11/17 13:30
Kiniksa Pharma Highlights Publication Of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020 In New England Journal Of Medicine
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that
Benzinga · 11/17 13:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KNSA. Analyze the recent business situations of Kiniksa Pharmaceuticals, Ltd. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KNSA stock price target is 34.00 with a high estimate of 40.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 135
Institutional Holdings: 29.54M
% Owned: 43.39%
Shares Outstanding: 68.08M
TypeInstitutionsShares
Increased
51
5.62M
New
36
2.89M
Decreased
15
1.09M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Chief Executive Officer/Director
Sanjiv Patel
Chief Financial Officer/Chief Accounting Officer
Michael Megna
Executive Vice President/Secretary
Thomas Beetham
Senior Vice President
John Paolini
Senior Vice President
Qasim Rizvi
Lead Director/Independent Director
Felix Baker
Director
G. Bradley Cole
Independent Director
Stephen Biggar
Independent Director
Richard Levy
Independent Director
Thomas Malley
Independent Director
Tracey McCain
Independent Director
Kimberly Popovits
Independent Director
Barry Quart
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KNSA
Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kiniksa Pharmaceuticals Ltd stock information, including NASDAQ:KNSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KNSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KNSA stock methods without spending real money on the virtual paper trading platform.